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Abstract An open cross-over and randomized study was carried out in order to compare the e⁄cacy and safety of
inhaled salbutamol delivered from a new 50 mgdoseÿ1metered-dose dry powder inhalerTaifuns, and a commercially
available 50 mgdoseÿ1drypowder inhalerTurbuhalers, and a conventional100 mgdoseÿ1pressurizedmetered-dose in-
haler with a spacer (pMDI+S).Twenty-one patients, aged 21^70 years, with stable asthma andwith demonstrated re-
versibilityuponinhalation of salbutamolwere includedinthe study.Onthree separate studydays, the patients received a
total dose of 400 mg of salbutamol fromthe drypowder inhalers and a dose of 800 mg fromthe pMDI+S in a cumulative
fashion:1,1, 2 and 4 doses at 30min intervals.Thepercentchange in forced expiratory volumein1sec (FEV1), wasused as
the primary e⁄cacy variable. Salbutamol inhaled via theTaifuns produced greater bronchodilation than the other de-
vices.The di¡erence in percent change in FEV1between theTaifun
s and the other deviceswas statistically signi¢cant at
the two ¢rst dose levels, but diminished towards the higher doses when the plateau of the dose^response curve was
reached.The estimatedrelative dosepotencyoftheTaifunswas approximately1?9- and 2?8-fold comparedtotheTurbu-
halersandthepMDI+S, respectively.TheTaifunscauseda slight, butclinicallyinsigni¢cant, decreasein serumpotassium
concentration.Therewereno signi¢cantchangesintheother safetyparameters (bloodpressure, heartrate andelectro-
cardiogram recordings) with any of the used devices. In conclusion, this study indicates that salbutamol inhaled via the
Taifuns ismore potentthan salbutamolinhaled fromthe otherdevices tested.Inpractise, a smaller totaldose of salbuta-
mol fromtheTaifuns is needed to produce a similar bronchodilatory response. All treatmentswere equally well tolera-
ted.r2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1189, available online at http://www.idealibrary.comon
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Inhaled, short-acting, selective b2-adrenoceptor
agonists, such as salbutamol, have played an important
role in the treatment of asthma and other conditions
associated with reversible airway obstruction. Their
rapid onset of action makes them the medication of
choice for the treatment of acute asthma attacks and
for the prophylaxis of exercise- and allergen-induced
bronchoconstriction (1).
The predominant formulation of inhaled medication
has been the chloro£uorocarbon (CFC)-basedReceived 8 January 2001, accepted in revised form13 July 2001and
published online 22 October 2001.
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of Pulmonary Diseases,Turku University Central Hospital, Paimion
Sairaala, FIN-21540 PreitilÌ, Finland.pressurized metered-dose inhaler (pMDI), which was
invented over 40 years ago and has remained practically
unchanged since. In addition to the fact that CFC gases
used inpMDIs deplete the ozone layerof our atmosphere
(2), they may irritate the bronchial mucous membranes
(3). Also, di⁄culties in co-ordinating the actuation of
the pMDI and inhaling the drug (4) are frequently seen.
These problems have led to the development of either
alternative propellants or entirely di¡erent devices,
metered dose powder inhalers (MDPI).With MDPIs all
that described above can be avoided, and they are now
generally considered as the devices of choice for future
inhalation therapy of asthma.
Recently, Leiras Oy has developed a new breath-
actuated MDPI, Taifuns (Fig. 1). It contains 200 doses of
salbutamol (50 or 100mgdoseÿ1) with lactose carrier,
provides a high respirable fraction (40^45% of the
TABLE 1. Summary of demographic characteristics of
the recruitedpatients (n=21)
Characteristic Mean7SD Range
Age (years) 50?4713?4 21^70
Weight (kg) 81?2717?3 60^136
Height (cm) 17079 156^191
FEV1 (l)
* 2?1370?59 1?05^3?36
FEV1of predicted (%) 62?5713?2 37^96
Reversibilityin FEV1after
salbutamol (%)*
23?3710?4 15?1^51?2
*Measured atthe screening visit.
950 RESPIRATORYMEDICINEdelivered dose) and with a mass median aerodynamic
diameter of 2?5^2?7mm, and is e⁄cient in delivering the
salbutamoldose into the lungs (5). In previous studies the
Taifuns proved to be at least as e¡ective in causing
bronchodilation (6) as one of thepMDIswith a spacerde-
vice (S), and better in o¡ering protection against metha-
choline-induced bronchoconstriction (7) than another
conventional pMDI+S. The aim of this study was to
compare the e⁄cacy and relative potency of cumulative
doses of salbutamol inhaled from the Taifuns
(50mgdoseÿ1) or via another MDPl (Turbuhalers) or a
pMDI+S.
METHODS
Design
This was a randomized, open, cross-over, cumulative
dose study, whichwas carried out in three clinics of pul-
monarydiseases in Finland.Each subject attended the la-
boratory three times after the screening visit. The
sessions were at least 24h apart, and the subjects com-
pleted the study within 2weeks from the screening visit.
Subjects
Twenty-one outpatients (nine males) with chronic
asthma, and a reversibility of forced expiratory volume
in 1sec (FEV1) of at least 15% measured 20min after
inhalation of 200mg of salbutamol from a Ventolines
pMDI connected to aVolumatics spacer were enrolled.
The patients ful¢lled the American Thoracic Society
criteria for asthma.The detaileddemographic character-
istics of the enrolled patients are listed in Table 1. All
patients were of Caucasian origin. Nine of them were
ex-smokers, the others had never smoked. Seventeen of
thepatients used inhaledglucocorticosteroids,13 inhaled
short-acting and six long-acting b2-adrenoceptor
agonists.One patient used a combination product of an
inhaledanticholinergic andb2-adrenoceptor agonist.Two
patients had inhaled chromones, and one was on anti-
histamine medication due to allergic rhinitis. Addition-
ally, six patients were on regular medication for other
than respiratory or allergic conditions; one patient took
an oestrogen supplement for menopausal symptoms,
two patients zopiclone for insomnia, two paracetamol
for musculoskeletal pains, one thyroxin for hypothyreo-
sis, and one patient isosorbide-5-mononitrate and
diltiazem for coronary artery disease.
Further, concomitant medication was withheld as
follows: inhaled short-acting b2-adrenoceptor agonists
for 12h, oral and inhaled long-acting b2-adrenoceptor
agonists for 48h, inhaled anti-cholinergics for 24h, oral
anti-cholinergics for 7 days, and theophylline and its
derivatives for 72h, prior to each study visit.
Concomitant medication with nasal, inhaled or oralglucocorticosteroids, or inhaled nedocromil or sodium
cromoglycate, with a constant dose for at least 1month
prior to and during the study was allowed.
The study was performed in accordance with the
principles stated in the Declaration of Helsinki and the
principles of Good Clinical Practice adopted by the Eur-
opean Community. The Finnish National Agency for
Medicines was noti¢ed of the study, and the study was
approved by the ethics committees of each hospital. All
subjects gave their signed informed consent before they
were enrolled in the study.
Instruments anddrugs
Pulmonary function was measured with Vitalograph
Compact IIs spirometers (Vitalograph Ltd., Bucking-
ham,U.K.) calibrated prior to the study.The calibration
was checked daily before any study measurements. The
equipmentwas used only for the present study.
The reversibility test was performed with an inhala-
tion of 200mg of salbutamol fromVentolines pMDI con-
nected to a Volumatics spacer (both from
GlaxoWellcome, Uxbridge, U.K.). The studied inhalers
wereTaifuns (Leiras Oy, Turku, Finland) giving 50mg of
salbutamol per dose with lactose carrier, salbutamol
50mgdoseÿ1 Turbuhalers (Astra AB, So dertaŒ lje, Swe-
den), and 100mgdoseÿ1 Ventolines Volumatics
(pMDI+S). In order to optimize the function of the de-
vices, inhalation techniques recommended by the manu-
facturers were followed. When using the Taifuns the
patients after having loaded the device exhaled normally
to functional capacity (FRC) and then took a normal, slow
tidal volume inhalation through the device.With theTur-
buhalers theprocedurewas similar, except that the inha-
lation through the device was deep and forceful. When
the pMDISwas used, after shaking the canister the pa-
tients exhaled to FRC, placed the mouthpiece ¢rmly be-
tween their lips and actuated the device, and after await
of 2^4 sec took a slow and deep inhalation. In order to
maximize lung deposition all inhalation procedures were
followedby a breath holding period of10 sec.
FIG. 1. TheTaifuns inhaler.
FIG. 2. The increase in FEV1 after each salbutamol dose.
Taifuns (-^-),Turbuhalers (-&), pMDI+S(*).
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The patients were randomized for the sequence of the
three inhalers, and inhaled salbutamol on three separate
days. On each study visit the baseline pulmonary
function was established by having the patients do
repeated spirometric e¡orts at intervals of 1min until
obtaining three FEV1 values from consecutive measure-
ments, of which at least two were within a range of
0?1^l. The better of these two values was recorded as
the baseline FEV1whichwas required to bewithin712%
from the baseline values of all other study days. All the
baseline measurements were performed at the same
time between 07?00 and11? 00 hours. Immediately after
them, cumulative doses of salbutamol were inhaled at
30min intervals as follows: from the Taifuns and
Turbuhalers1+1+2+4 inhalations with cumulative doses
of 50, 100, 200 and 400mg of salbutamol; from the
pMDI+S 1+1+2+4 inhalations with doses of 100, 200,
400 and 800mg of salbutamol. Pulmonary function was
measured 25min after each drug dose, and the FEV1
from the best technically valid spirometric e¡ort of
threewas recorded.
As safety precautions, every patient’s electrocardio-
gram (ECG), blood pressure (BP) and heart rate (HR)
were recorded during the study. ECG was recorded
before and after the study procedures. BP and HRwere
recorded before the ¢rst drug inhalation and 20 min
after each dose. Also blood samples for analysing serum
potassium (S-K) levels were collected before the ¢rst,
and 30 min after the last, drug inhalation.
Data analysis
The results are presented as means and standard
deviations (SD), unless otherwise indicated. All analyses
were based on the intent-to-treat population. Per cent
change in FEV1 from the baseline was used as the
primary e⁄cacy variable. A one-sided 95% con¢dence
interval (95% CI), corresponding to a two-sided 90%
CI (90% CI), based on the least square of means was
calculated to test the non-inferiority of the Taifuns in
comparison with the other devices. If Taifuns was
detected to be at least as e¡ective as the other devices,
analysis of variance (ANOVA) with a 33 cross-over
design or corresponding non-parametric method was
performed. ANOVAwas performed also for numerical
safety parameters. A P-value of less than 0?05 was
considered statistically signi¢cant. Also, to support
the results of the primary e⁄cacy parameter, the
relative dose potency of the devices was calculated
by estimating the parallel shift of the dose-response
curves by applying a linear model: e¡ect= subject+
device+period+log-dose. A normal two-sided 95%
con¢dence interval (95% CI) was calculated for this
parameter.RESULTS
All but two of the recruited patients completed the
study according to the protocol. Both discontinuations
were due to exacerbation of asthma. The mean (SD)
baseline FEV1 values of the Taifun
s, Turbuhalers and
pMDI+S periods were 2?12 (0?59) l, 2?11 (0?62) l and 2?17
(0?58) l, respectively. The cumulative salbutamol doses
caused bronchodilation increasing dose by dose, which
at the ¢rst two doses was most prominent with the
Taifuns, followed by the Turbuhalers and then the
pMDI+S (Fig. 2). At the ¢rst two dose steps theTaifuns
di¡ered signi¢cantly from the other devices, the
Turbuhalers (P=0?037 for the ¢rst and P=0?007 for
the second dose) and the pMDI+S (P=0?019 for the ¢rst
and P=0?028 for the second dose) (Table 2). At higher
dose levels (200 and 400mg for the Taifuns and the
Turbuhalers, 400 and 800mg for the pMDI+S) the
di¡erence between the devices diminished, being no
longer signi¢cant, but the order of e⁄cacy remained
(Fig. 2, Table 2). The estimated relative dose
potency (95% CI) of the Taifuns was 1?9 (1?4^2?6) and
2?8 (2?1^3?8) when compared to the Turbuhalers and
pMDI+S, respectively. The relative potency of the
TABLE 2. The di¡erence in per cent changes between theTaifuns and other studied devices presented as % units and two-
sided 90% con¢dence intervals in brackets (90% CI)
Dose fromtheTaifuns
50 mg 100 mg 200 mg 400 mg
Turbuhalers 5?2 (1.1^9?4)
50 mg
100 mg 4?9 (1?9^7?9)
200 mg 1?5 (ÿ1?8^4? 8)
400 mg 1?5 (ÿ2?7^5?6)
PMDI+S
100 mg 5?9 (1?7^10?0)
200 mg 4?0 (1?0^6?9)
400 mg 2?9 (ÿ0?4^6?3)
800 mg 1?6 (ÿ2?5^5?8)
952 RESPIRATORYMEDICINETurbuhalers was estimated to be1?5 (1?1^2?0) of that of
the pMDI+S.
All S-K concentrations measured during the study
were within the normal range (3?5^5?1mmolÿ1). The
mean (SD) baseline S-K levels were 4?22 (0?19), 4?12
(0?28) and 4?25 (0?24) mmol lÿ1 at the Taifuns, Turbu-
halers and pMDI+S periods, respectively. After the
salbutamol inhalations the corresponding values were
4?12 (0?22), 4?21 (0?22) and 4?15 (0?30) mmol lÿ1. The
di¡erence between the Taifuns and the Turbuhalers
was statistically signi¢cant, ÿ0?19 (95% CI ÿ0?33 to
0?05).TheTaifuns and the pMDI+S did not di¡er in this
respect fromeach other; the di¡erence in S-Kvalueswas
0?01 (95% CI ÿ0?15 to 0?12).The baseline BP, HR or ECG
did not di¡er between medications and there were no
signi¢cant changes in these parameters during the
di¡erent treatments.
There were 10 reported AEs, altogether, in ¢ve
patients during the study: two after theTaifuns, three
after theTurbuhalers and four after thepMDI+S period.
Of these only four AEs in two patients were probably
drug-related: one event of tremor after each treatment
and one report of dizziness after Turbuhalers treat-
ment.
DISCUSSION
The development of new inhalation devices raises the
question of their relative e⁄cacy.This investigation was
carried out in order to compare the e⁄cacy of a new
salbutamol MDPI, Taifuns, with that of another MDPI
and a conventional pMDI with a spacer containing the
same active drug substance.Whencomparingdi¡erent in-
halers, itwouldhave been preferable to employ a double-
blind and double-dummy technique. However, for
reasons of simplicity and feasibility it was decided not to
utilize this technique in the study design. For the samereason also placebo control was left out of the study.
The lack of blindness in comparing the devices
may slightly reduce the value of this study since this
allows, at least theoretically, some bias to occur in the
measurements.The di¡erences in the e⁄cacy measure-
ments between devices were, however, consistent and
clear, and also there were no di¡erence in the safety
parameters between the devices, which indicates that
this fault in the studydesignhadprobably nomajor e¡ect
on the results. Sincemost patients inhaled the ¢rst dose
quite early in themorning, in the absence of a placebo it
cannot be precluded that natural increase in pulmonary
function due to the circadian rhythm (8) might also have
contributed to the bronchodilation seen.This, however,
has no e¡ect on thebetween-device comparison and the
main results of this study.
This is the ¢rst time theTaifunswas compared to any
other MDPI. It is considered that the clinical e⁄cacy of
inhaledb2-adrenoceptor agonist drugs is directly related
to their lung deposition (9,10). There is no published
data available of pulmonary deposition of salbutamol
inhaled from theTurbuhalers.However,with terbutaline
Turbuhalers previous deposition studies show
approximately similar lung drug deposition (21^28%) as
with salbutamol Taifuns (24%) (5,11,12). There are
some previous studies comparing the relative e⁄cacy
of salbutamol Turbuhalers to various other inhalation
devices. The Turbuhalers has proven to be a very
e⁄cient inhaler since in these studies it has been
shown to be about twice as e¡ective as Diskhalers or
Rotahalers (13,14), and about two to three times as
e¡ective as a pMDI (15). When comparing the Taifuns
and the pMDI+S, the results of this study are in
accordance with an earlier study (7) where ability of a
single dose of 100mg of salbutamol inhaled via the
Taifuns to protect against methacholine-induced
bronchoconstriction was found to be clearly better
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pMDI+S (PD20FEV1 1737mg vs. 622mg). However, there
are no previous studies where the Taifuns has been
compared with other powder inhalers, or with a wide
range of di¡erent salbutamol doses with any other
inhaler devices.
When planning the present study it was assumed that
the salbutamol Taifuns and Tubuhalers would have
approximately the same level of performance. Bearing
in mind the results of a previous study (7), it was
expected thathigher salbutamoldoses from the pMDI+S
wouldbeneeded to gain a similar level of performance as
with theTaifuns.Consequently, the doses of salbutamol
were selected to start from the smallest available dose
from each device and range up to 400mg for the MDPIs
and to 800mg for the pMDI+S.The hypothesis was that
at each dose level salbutamol inhaled via the Taifuns
would be at least as e¡ective as salbutamol inhaled via
theTurbuhalers or the pMDI+S.
Salbutamol inhaled via theTaifuns produced at each
dose level greater bronchodilation than equal doses of
salbutamol inhaled via the Turbuhalers or twice as
high nominal doses from the pMDI+S. At the two
lowest doses levels the resulted bronchodilation was
signi¢cantly greater with the Taifuns than with the
Turbuhalers or the pMDI+S, respectively. Thereafter,
towards the higher doses, the di¡erences between the
devices diminished, being no longer statistically
signi¢cant as the plateau of the dose^response curve
was achieved. On the basis of these results it can be
estimated that the relative dose potency of salbutamol
from theTaifuns is about twice that of theTurbuhalers
and about three times that of the pMDI+S.
The overall safety of the tested devices seemed to be
similar. The reported drug-related adverse e¡ects were
mild and were distributed rather evenly between the
devices. In previous studies (16,17) the hypokalaemic
e¡ect of inhaled salbutamol (via a pMDI and a spacer)
became evident at a dose level of 500mg or higher.
Consequently, some changes in potassium concentra-
tions were expected in the present study. Indeed,
potassium concentrations seemed to decrease slightly
after the usage of the Taifuns and the pMDI+S, as
expected.On the contrary, an unexplained increasewas
seen after theTurbuhalers. Although the actual changes
in serum potassium concentrations with all the devices
were small and clinically insigni¢cant, this resulted
in a statistically signi¢cant di¡erence in potassium
concentrations after salbutamol dosing between the
Taifuns and theTurbuhalers.
In conclusion, the salbutamol Taifunswas found to be
more potent in producing bronchodilaton in asthmatic
patients than the salbutamol Turbuhalers or salbutamol
pMDI connected to aVolumatics spacer. Approximately
two doses from theTurbuhalers and three doses from
the pMDI+Volumatics were needed to producebronchodilation of similar magnitude than a single dose
from theTaifuns. It is always an advantage if the patient
can be burdened with as small as possible total dose,
inhaled and swallowed, of the drug, and still get relief to
the symptoms of asthma. All treatments were equally
well tolerated.
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